9 Meters Biopharma, Inc.
Not enough financial coverage to compute a composite score for NMTRQ. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companywww.9meters.com
9 Meters Biopharma, Inc. , a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome.
- CEO
- Peter H. R. Green
- IPO
- 2016
- Employees
- 10
- HQ
- Raleigh, NC, US
Price Chart
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 10.00
- Avg Volume
- 105
Get TickerSpark's AI analysis on NMTRQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NMTRQ Coverage
We haven't published any research on NMTRQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NMTRQ Report →